Literature DB >> 24264313

Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.

Lin Zhao1, Shimiao Zhu, Ying Gao, Yaogang Wang.   

Abstract

A HOXB13-to-IL17BR expression ratio was previously identified to predict a clinical outcome of breast cancer patients treated with adjuvant tamoxifen. A large number of studies were addressed to confirm its function as a predictor of breast cancer outcome treated with tamoxifen. However, conflicting results were got. In this study, a systematic search of databases was carried out, and other relevant papers were also identified. Then, the analyses were conducted according to the PRISMA and MOOSE guidelines. After full review, 11 studies with a total of 2,958 participants were deemed eligible and were included in the study. Pooled results revealed that women with higher HOXB13-to-IL17BR expression ratio had significantly worse outcomes in breast patients treated with tamoxifen, especially for those who are negative of node.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24264313     DOI: 10.1007/s13277-013-1403-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Limits of predictive models using microarray data for breast cancer clinical treatment outcome.

Authors:  James F Reid; Lara Lusa; Loris De Cecco; Danila Coradini; Silvia Veneroni; Maria Grazia Daidone; Manuela Gariboldi; Marco A Pierotti
Journal:  J Natl Cancer Inst       Date:  2005-06-15       Impact factor: 13.506

2.  HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Authors:  Nilay Shah; Kideok Jin; Leigh-Ann Cruz; Sunju Park; Helen Sadik; Soonweng Cho; Chirayu Pankaj Goswami; Harikrishna Nakshatri; Rajnish Gupta; Howard Y Chang; Zhe Zhang; Ashley Cimino-Mathews; Leslie Cope; Christopher Umbricht; Saraswati Sukumar
Journal:  Cancer Res       Date:  2013-07-05       Impact factor: 12.701

3.  Concordance among gene-expression-based predictors for breast cancer.

Authors:  Cheng Fan; Daniel S Oh; Lodewyk Wessels; Britta Weigelt; Dimitry S A Nuyten; Andrew B Nobel; Laura J van't Veer; Charles M Perou
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

4.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.

Authors:  H Okuda; M Toyota; W Ishida; M Furihata; M Tsuchiya; M Kamada; T Tokino; T Shuin
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

6.  The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.

Authors:  Xiao-Jun Ma; Susan G Hilsenbeck; Wilson Wang; Li Ding; Dennis C Sgroi; Richard A Bender; C Kent Osborne; D Craig Allred; Mark G Erlander
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.

Authors:  Piiha-Lotta Jerevall; Sara Brommesson; Carina Strand; Sofia Gruvberger-Saal; Per Malmström; Bo Nordenskjöld; Sten Wingren; Peter Söderkvist; Mårten Fernö; Olle Stål
Journal:  Breast Cancer Res Treat       Date:  2007-04-24       Impact factor: 4.872

Review 8.  Risk factors and prevention of inguinal hernia after radical prostatectomy: a systematic review and meta-analysis.

Authors:  Shimiao Zhu; Hui Zhang; Linguo Xie; Jing Chen; Yuanjie Niu
Journal:  J Urol       Date:  2012-09-23       Impact factor: 7.450

9.  Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Authors:  Marleen Kok; Sabine C Linn; Ryan K Van Laar; Maurice P H M Jansen; Teun M van den Berg; Leonie J M J Delahaye; Annuska M Glas; Johannes L Peterse; Michael Hauptmann; John A Foekens; Jan G M Klijn; Lodewyk F A Wessels; Laura J Van't Veer; Els M J J Berns
Journal:  Breast Cancer Res Treat       Date:  2008-03-04       Impact factor: 4.872

10.  Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies.

Authors:  Hui Zhang; Shimiao Zhu; Jing Chen; Yang Tang; Hailong Hu; Viswanathan Mohan; Radha Venkatesan; Jianmin Wang; Haiping Chen
Journal:  Diabetes Care       Date:  2012-06       Impact factor: 19.112

View more
  2 in total

1.  Diseases and Molecular Diagnostics: A Step Closer to Precision Medicine.

Authors:  Shailendra Dwivedi; Purvi Purohit; Radhieka Misra; Puneet Pareek; Apul Goel; Sanjay Khattri; Kamlesh Kumar Pant; Sanjeev Misra; Praveen Sharma
Journal:  Indian J Clin Biochem       Date:  2017-08-22

2.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.

Authors:  Jingjing Liu; Wendy J C Prager-van der Smissen; J Margriet Collée; Manjeet K Bolla; Qin Wang; Kyriaki Michailidou; Joe Dennis; Thomas U Ahearn; Kristiina Aittomäki; Christine B Ambrosone; Irene L Andrulis; Hoda Anton-Culver; Natalia N Antonenkova; Volker Arndt; Norbert Arnold; Kristan J Aronson; Annelie Augustinsson; Päivi Auvinen; Heiko Becher; Matthias W Beckmann; Sabine Behrens; Marina Bermisheva; Leslie Bernstein; Natalia V Bogdanova; Nadja Bogdanova-Markov; Stig E Bojesen; Hiltrud Brauch; Hermann Brenner; Ignacio Briceno; Sara Y Brucker; Thomas Brüning; Barbara Burwinkel; Qiuyin Cai; Hui Cai; Daniele Campa; Federico Canzian; Jose E Castelao; Jenny Chang-Claude; Stephen J Chanock; Ji-Yeob Choi; Melissa Christiaens; Christine L Clarke; Fergus J Couch; Kamila Czene; Mary B Daly; Peter Devilee; Isabel Dos-Santos-Silva; Miriam Dwek; Diana M Eccles; A Heather Eliassen; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Lin Fritschi; Manuela Gago-Dominguez; Susan M Gapstur; Montserrat García-Closas; José A García-Sáenz; Mia M Gaudet; Graham G Giles; Mark S Goldberg; David E Goldgar; Pascal Guénel; Christopher A Haiman; Niclas Håkansson; Per Hall; Patricia A Harrington; Steven N Hart; Mikael Hartman; Peter Hillemanns; John L Hopper; Ming-Feng Hou; David J Hunter; Dezheng Huo; Hidemi Ito; Motoki Iwasaki; Milena Jakimovska; Anna Jakubowska; Esther M John; Rudolf Kaaks; Daehee Kang; Renske Keeman; Elza Khusnutdinova; Sung-Won Kim; Peter Kraft; Vessela N Kristensen; Allison W Kurian; Loic Le Marchand; Jingmei Li; Annika Lindblom; Artitaya Lophatananon; Robert N Luben; Jan Lubiński; Arto Mannermaa; Mehdi Manoochehri; Siranoush Manoukian; Sara Margolin; Shivaani Mariapun; Keitaro Matsuo; Tabea Maurer; Dimitrios Mavroudis; Alfons Meindl; Usha Menon; Roger L Milne; Kenneth Muir; Anna Marie Mulligan; Susan L Neuhausen; Heli Nevanlinna; Kenneth Offit; Olufunmilayo I Olopade; Janet E Olson; Håkan Olsson; Nick Orr; Sue K Park; Paolo Peterlongo; Julian Peto; Dijana Plaseska-Karanfilska; Nadege Presneau; Brigitte Rack; Rohini Rau-Murthy; Gad Rennert; Hedy S Rennert; Valerie Rhenius; Atocha Romero; Matthias Ruebner; Emmanouil Saloustros; Rita K Schmutzler; Andreas Schneeweiss; Christopher Scott; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Jacques Simard; Christof Sohn; Melissa C Southey; John J Spinelli; Rulla M Tamimi; William J Tapper; Soo H Teo; Mary Beth Terry; Diana Torres; Thérèse Truong; Michael Untch; Celine M Vachon; Christi J van Asperen; Alicja Wolk; Taiki Yamaji; Wei Zheng; Argyrios Ziogas; Elad Ziv; Gabriela Torres-Mejía; Thilo Dörk; Anthony J Swerdlow; Ute Hamann; Marjanka K Schmidt; Alison M Dunning; Paul D P Pharoah; Douglas F Easton; Maartje J Hooning; John W M Martens; Antoinette Hollestelle
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.